重新评估羟基脲在真性红细胞增多症中的获益-风险特征:一项倾向匹配研究
该研究基于ECLAP研究队列,选取1042例仅接受放血或羟基脲治疗以维持血细胞比容<45%的真性红细胞增多症患者,经倾向评分匹配后比较两组结局。结果显示羟基脲组致死/非致死性心血管事件发生率显著低于放血组(3.0 vs 5.8/100人年,P=0.002),骨髓纤维化转化仅见于放血组,急性白血病转化共3例。
要点
- 羟基脲组心血管事件发生率显著低于放血组(3.0 vs 5.8/100人年,P=0.002)。
- 骨髓纤维化转化仅发生于放血组患者。
- 放血组死亡和心血管事件超额仅见于高危组及未达血细胞比容目标者。
核心结论
- 该分析为羟基脲和放血治疗提供了可靠的疗效估计,可供未来实验研究和临床实践管理真性红细胞增多症参考。
研究设计与样本
- 基于欧洲协作低剂量阿司匹林(ECLAP)研究队列,选取1042例随访期间仅接受放血或羟基脲治疗以维持血细胞比容<45%的真性红细胞增多症患者,并进行倾向评分匹配分析。
主要发现
- 匹配后放血组342例,羟基脲组681例,倾向评分参数均衡(总体平衡χ2=2.44,P=0.964)。
- 随访期放血组29.9个月,羟基脲组34.7个月,羟基脲组致死/非致死性心血管事件发生率显著低于放血组(3.0 vs 5.8/100人年,P=0.002)。
- 骨髓纤维化转化仅见于放血组患者。
- 急性白血病转化共3例(放血组2例,羟基脲组1例)。
- 放血组死亡和总心血管事件的超额仅见于高危组,且与羟基脲组相比,未达到血细胞比容目标<0.45%的放血组患者显著更高(P=0.000)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of hydroxyurea (HU) as first line therapy in polycythemia vera (PV) has been criticized because no solid demonstration that this drug prevents thrombosis or prolongs survival has been so far produced. Here we present the outcomes of a large cohort of patients with PV included in the European Collaborative Low-dose Aspirin (ECLAP) study. We selected 1,042 patients who, during the follow-up, had received only phlebotomy (PHL) or HU to maintain the hematocrit level < 45%. To assure comparability, we conducted a propensity score matching analysis. The two groups (PHL n = 342 and HU n = 681) were well balanced for the parameters included in the propensity score (overall balance: χ2 = 2.44, P = 0.964). Over a comparable period of follow-up (PHL = 29.9 vs. HU = 34.7 months), we documented an advantage of HU over PHL consistently significant with respect to the incidence of fatal/non-fatal cardiovascular (CV) events (5.8 vs. 3.0 per 100 person-years in PHL vs. HU group, P = 0.002) and myelofibrosis transformation that was only experienced by patients of PHL group. Evolution to acute leukemia was registered in three patients (two in PHL and one in HU group). The excess of mortality and total CV events in the PHL patients was restricted to the high-risk group, and, compared with HU cases, was significant higher in the PHL patients who failed to reach the hematocrit target < 0.45% (P = 0.000). In conclusion, this analysis provides reliable and qualified estimates of the therapeutic profile of HU and PHL treatments for future experimental studies and for the management of PV in clinical practice.
引用
- Barbui T, Vannucchi AM, Finazzi G, et al. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. Am J Hematol. 2017. PMID: 28699191. doi:10.1002/ajh.24851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。